Subcutaneous administration of foslevodopa/foscarbidopa (PRODUODOPA ® ) in arm and thigh due to giant epigastric hernia: a case report.

Autor: Telarović S; School of Medicine, University of Zagreb, Zagreb, Croatia.; Department of Neurology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, 10000, Croatia., Čondić Jurjević L; Department of Neurology, General Hospital dr. Ivo Pedišić, Josipa Jurja Strossmayera 59, Sisak, 44000, Croatia. lucija.condic@gmail.com.
Jazyk: angličtina
Zdroj: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2024 Dec 18. Date of Electronic Publication: 2024 Dec 18.
DOI: 10.1007/s10072-024-07928-4
Abstrakt: Background: PRODUODOPA ® is a combination of foscarbidopa and foslevodopa indicated for the treatment of motor fluctuations in patients with advanced Parkinson's disease when available combinations of peroral drugs have not given satisfactory results. The solution is administered via subcutaneous infusion, most frequently in the abdomen, using an infusion pump. The study results showed a significant effect on the reductions in off time and higher control of motor symptoms without troublesome dyskinesia.
Case Description: A 61-year-old man on long-term oral therapy for Parkinson's disease presented with frequent wearing-off phenomenon, daily freezing episodes and occasional episodes of severe nocturnal akinesia. Due to giant epigastric hernia PRODUODOPA was administered subcutaneously in upper arm and thigh. The use of the pump resulted in an excellent therapeutic effect with a reduction in motor fluctuations and an improvement in the patient's quality of life. From the available medical literature, the use of the drug in the limb area has not been described so far.
Conclusion: PRODUODOPA can be administered subcutaneously in the area of ​​the upper and lower extremities with just as good results as after subcutaneous infusion in abdomen.
Competing Interests: Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Institutional review board approval: Informed consent was obtained from patient included in the study. Consent for publication: The patient has consented to the submission of the case report to the journal. Disclaimer: The authors declare that the proposed manuscript describes original research and is not published or under consideration by another scientific journal. The data/results of the manuscript are not plagiarized.
(© 2024. Fondazione Società Italiana di Neurologia.)
Databáze: MEDLINE
Externí odkaz: